Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07456371) titled 'PIC1 Injection Therapy for Relapsed/Refractory B-NHL' on March 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Chongqing Precision Biotech Co., Ltd

Condition: Non-Hodgkin Lymphoma

Intervention: Biological: PIC1 Injection

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: March 2026

Target Sample Size: 18

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07456371

Published by HT Digital Content Services with permi...